Results 41 to 50 of about 210,319 (126)
Journal of Medical Case Reports, 2023 Background Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past ...
Eng-Loon Tng +2 more
doaj +1 more source
Impulse control disorders and dopamine agonists
European Psychiatry, 2021 Introduction Impulse control disorders (ICDs) are an adverse effect of dopamine agonists (DAAs) that affects the quality of life and can lead to legal, criminal and familiar problems.
D. Martins +3 more
doaj +1 more source
Dopamine Agonists: From the 1970s to Today
, 2019 The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting ...
DE ALCUBIERRE, DARIO +5 more
core +1 more source
Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease
Frontiers in NeurologyIntroductionImpulse control disorders (ICDs) are defined as excessive and repetitive behaviors that may affect Parkinson’s disease (PD) patients exposed to dopamine agonists. Current data on ICDs in patients with early-onset Parkinson’s disease (EOPD) is
Pierpaolo Turcano +8 more
doaj +1 more source
NeuroImage: Clinical, 2017 We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls.
Marios Politis +4 more
doaj +1 more source
, 2001 The dopamine D-3 receptor is predominantly expressed in limbic regions of the brain, such as the nucleus accumbens, island of Calleja and hippocampus, and is known to be associated with cognitive and emotional functions. This neuroanatomical distribution
Maloteaux, Jean-Marie +3 more
core +1 more source
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
Медицинский совет, 2020 Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic ...
O. S. Levin +2 more
doaj +1 more source
The Role of Opioids on Motor Activity in Physio-pathological Conditions [PDF]
, 2009 To date, four principal classes of opioid peptide receptors, μ (MOP), κ (KOP), δ (DOP) and ORL- 1 (NOP) have been identified and cloned. The experimental and clinical importance of this receptor family has been amply demonstrated in many diseases ...
Mabrouk, Omar Sharif
core
Dopamine Partial Agonists in Pregnancy and Lactation: A Systematic Review
PharmaceuticalsBackground/Objectives: Dopamine partial agonists are drugs initially developed to treat schizophrenia, seeking a double effect of increased dopaminergic transmission in the prefrontal cortex and decrease in the accumbens/striatum.
Alexia Koukopoulos +13 more
doaj +1 more source
Dopamine-Deficient Mice Are Hypersensitive to Dopamine Receptor Agonists
, 2000 Dopamine-deficient (DA−/−) mice were created by targeted inactivation of the tyrosine hydroxylase gene in dopaminergic neurons. The locomotor activity response of these mutants to dopamine D1 or D2 receptor agonists andl-3,4-dihydroxyphenylalanine (l ...
Mark S. Szczypka +2 more
core +1 more source